| Company Name: |
Wuxi AppTec
|
| Tel: |
022-59987777 13552403979 |
| Email: |
jia_guoqiang@wuxiapptec.com |
| Products Intro: |
Product Name:(S)-2-(2-chloro-6-methylbenzamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid
CAS:220846-33-3
Purity:0.95 Package:100g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:RO0270608
CAS:220846-33-3
Purity:98.55% Package:1mg/RMB 1290;5mg/RMB 2880;10mg/RMB 4790
|
| Company Name: |
Suzhou Meishi Biotechnology Co., Ltd.
|
| Tel: |
1173954148q |
| Email: |
meishipharma@126.com |
| Products Intro: |
Product Name:220846-33-3
CAS:220846-33-3
Purity:99% HPLC Package:1G;5G;10G;100G;1KG;
|
(S)-2-(2-chloro-6-methylbenzamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid(WXG00491) manufacturers
- RO0270608
-
- $117.00 / 1mg
-
2025-11-10
- CAS:220846-33-3
- Min. Order:
- Purity: 98.26%
- Supply Ability: 10g
|
| | (S)-2-(2-chloro-6-methylbenzamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid(WXG00491) Basic information |
| | (S)-2-(2-chloro-6-methylbenzamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid(WXG00491) Chemical Properties |
| Boiling point | 633.0±55.0 °C(Predicted) | | density | 1.447±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | pka | 3.60±0.10(Predicted) | | form | Solid | | color | Off-white to light yellow |
| | (S)-2-(2-chloro-6-methylbenzamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid(WXG00491) Usage And Synthesis |
| Uses | RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist. Antiinflammatory activity[1][2]. | | in vivo | In a murine OVA-model of airway inflammation, RO0270608 i.n. abolishes allergen-induced inflammatory cell accumulation[2] | | IC 50 | α4β1; α4β7 | | References | [1] Hijazi Y, et al. Pharmacokinetics, safety, and tolerability of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers. J Clin Pharmacol. 2004;44(12):1368-1 DOI:10.1177/0091270004270147
[2] M. Renzetti, et al. Dual α4/β1–α4/β7 vs α4/β1 selective antagonism is required for attenuation of allergic inflammatory responses. Journal of Allergy and Clinical Immunology. Volume 113, Issue 2, Supplement, February 2004, Page S221. |
| | (S)-2-(2-chloro-6-methylbenzamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid(WXG00491) Preparation Products And Raw materials |
|